首页> 外文期刊>ORL: Journal for oto-rhino-laryngology and its borderlands >Induction of tolerance by oral administration of beta-tubulin in an animal model of autoimmune inner ear disease.
【24h】

Induction of tolerance by oral administration of beta-tubulin in an animal model of autoimmune inner ear disease.

机译:在自身免疫性内耳疾病的动物模型中口服β-微管蛋白诱导耐受性。

获取原文
获取原文并翻译 | 示例
           

摘要

Induction of peripheral tolerance by oral administration of low-dose beta-tubulin antigen may be an effective, antigen-specific method to suppress experimental autoimmune hearing loss. Five groups of mice were fed with phosphate-buffered saline (PBS), ovalbumin (OVA), 20, 30 or 200 microg of beta-tubulin, respectively. All mice were then immunized by beta-tubulin. Hearing thresholds were measured before and after immunization. Inner ear histology and cytokine profile were examined. Mice fed with 20 or 30 microg of beta-tubulin showed less hearing loss and less inner ear damage compared to the groups treated with PBS, OVA or 200 microg of beta-tubulin. Interferon-gamma (IFN-gamma) was decreased while interleukin-4 (IL-4), IL-5, IL-13 and TGF-beta were increased in both sera and in cell culture supernatants of the mice fed with 20 or 30 microg of beta-tubulin. However, no cytokine profile change was found in the group treated with 200 microg of tubulin. These results suggest that a low dose of beta-tubulin is active orally in an antigen-specific fashion and capable of inhibiting the autoimmune reactions in the inner ear by suppressing Th1 (IFN-gamma) and increasing Th2 and Th3 (IL-4, IL-5, IL-13 and TGF-beta) cytokines. Oral antigen tolerance may be used to treat autoimmune inner ear disease.
机译:通过口服低剂量的β-微管蛋白抗原诱导外周耐受可能是抑制实验性自身免疫性听力损失的有效抗原特异性方法。五组小鼠分别饲喂磷酸盐缓冲盐水(PBS),卵清蛋白(OVA),20、30或200微克β-微管蛋白。然后用β-微管蛋白免疫所有小鼠。在免疫前后测量听力阈值。检查内耳组织学和细胞因子谱。与用PBS,OVA或200微克β-微管蛋白治疗的组相比,喂食20或30微克β-微管蛋白的小鼠表现出较少的听力损失和内耳损伤。用20或30微克喂食的小鼠的血清和细胞培养上清液中的干扰素-γ(IFN-γ)降低而白细胞介素4(IL-4),IL-5,IL-13和TGF-β升高。 β微管蛋白。然而,在用200微克微管蛋白治疗的组中未发现细胞因子谱变化。这些结果表明,低剂量的β-微管蛋白以抗原特异性方式口服,并且能够通过抑制Th1(IFN-γ)并增加Th2和Th3(IL-4,IL)来抑制内耳的自身免疫反应。 -5,IL-13和TGF-β)细胞因子。口服抗原耐受性可用于治疗自身免疫性内耳疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号